Sonas Pharma has closed a pre-seed funding round backed by SFC Capital and Clarendon Fund Managers. The Sonas Pharma pre-seed investment will support early-stage research programmes in obesity and epilepsy, as the company develops candidates targeting the endocannabinoid system.
Sonas Pharma pre-seed investment supports early-stage R&D
Representatives at the Sonas Pharma pre-seed funding announcement.
The company said the financing will be used to advance a CB1-focused metabolic programme and to continue development of its epilepsy discovery platform. In addition, Sonas Pharma plans to expand core R&D capability and early translational work.
Sonas Pharma is based in Northern Ireland and is registered as a biotechnology R&D business. Public records list the company as active under UK company filings.
Investors include SFC Capital and Clarendon Fund Managers
The round was led by SFC Capital, an early-stage investor that supports UK start-ups. Clarendon Fund Managers also participated through its co-investment activity.
Clarendon manages Co-Fund NI, part of Invest Northern Ireland’s wider access-to-finance framework for local SMEs. As a result, the investment links private capital with regional support mechanisms for early-stage businesses.
Therapeutic focus on obesity and epilepsy
Sonas Pharma said its pipeline work is centred on the endocannabinoid system, including approaches designed to limit activity outside target tissues. However, the company has not disclosed clinical timelines or programme-stage detail in the announcement.
Related coverage is available in the Life Sciences Global News Pharmaceuticals section.
